Glympse Bio Announces $46.7M Series B Financing

by vcaonline.com posted 2months ago 16 views
CAMBRIDGE, Mass., July 15, 2020-- Glympse Bio (Glympse), a biotechnology company advancing the way diseases are understood, tracked, and treated, has closed an oversubscribed $46.7 million Series B financing. The proceeds from the financing will support continued development of Glympse's novel biosensor platform in fibrotic diseases such as Non-Alcoholic Steatohepatitis (NASH), oncology, and infectious diseases.

In this article